242 related articles for article (PubMed ID: 27616351)
1. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
Lal S; Zarei M; Chand SN; Dylgjeri E; Mambelli-Lisboa NC; Pishvaian MJ; Yeo CJ; Winter JM; Brody JR
Sci Rep; 2016 Sep; 6():33323. PubMed ID: 27616351
[TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
3. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
[TBL] [Abstract][Full Text] [Related]
4. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
5. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
[TBL] [Abstract][Full Text] [Related]
6. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
8. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
[TBL] [Abstract][Full Text] [Related]
10. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
12. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
[TBL] [Abstract][Full Text] [Related]
13. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
[TBL] [Abstract][Full Text] [Related]
16. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
17. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A
Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782
[TBL] [Abstract][Full Text] [Related]
18. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
[TBL] [Abstract][Full Text] [Related]
20. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
